The Diabetic Foot Ulcers Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Diabetic Foot Ulcers Pipeline Insight, 2026″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Foot Ulcers Market.

Get a Free Sample PDF Report to know more about Diabetic Foot Ulcers Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/diabetic-foot-ulcers-pipeline-insight

Some of the key takeaways from the Diabetic Foot Ulcers Pipeline Report:

• Companies across the globe are diligently working toward developing novel Diabetic Foot Ulcers treatment therapies with a considerable amount of success over the years.

• Diabetic Foot Ulcers companies working in the treatment market are Topadur Pharma, Cynata Therapeutics, Transwell Biotech, Aposcience, Ilya Pharma, Microbion Corporation, MediWound, Paracrine, INC., NovaLead Pharma, and others, are developing therapies for the Diabetic Foot Ulcers treatment

• Emerging Diabetic Foot Ulcers therapies in the different phases of clinical trials are- TOP-N53, CYP-006TK, TWB-103, APO-2, ILP100, MBN-101, EscharEx, Adipose-derived regenerative cells, Galnobax, and others are expected to have a significant impact on the Diabetic Foot Ulcers market in the coming years.

• In October 2026, PuraPly AM trial results published: Organogenesis announced publication of the PREPARE randomized controlled trial results for PuraPly AM, an antimicrobial collagen matrix used alongside standard care for hard-to-heal DFUs. The study met its primary endpoint and reported statistically significant improvements in wound closure at 12 weeks. PuraPly AM is indicated for wound management, including DFUs; this announcement concerns clinical evidence, not a new FDA approval.

• In September 2026, XWRAP trial completes patient follow-up: Applied Biologics announced that the last patient had completed the final visit in its CAMPX randomized controlled trial evaluating XWRAP alongside standard care versus standard care alone for chronic diabetic foot ulcers. The study was moving toward database lock and final statistical analysis.

• In September 2026, Nu-3 advances toward Phase IIa clinical testing: Lakewood-Amedex Biotherapeutics announced institutional review board approvals and clinical-site readiness for a Phase IIa trial of Nu-3 in patients with mildly infected diabetic foot ulcers. The investigational antimicrobial is being studied for safety and efficacy, with an emphasis on treating wound infections

• In September 2026, BIOxHEAL Phase III trial site activated: Applied Biologics announced activation of the first clinical research site for its randomized, multicenter Phase III BIOxHEAL trial. The study is designed to compare BIOxHEAL plus standard care with standard care alone in patients with chronic, nonhealing DFUs.

• In July 2026, PL-5 antimicrobial spray demonstrates clinical benefit in infected DFUs: A multicenter, randomized, double-blind, placebo-controlled clinical trial published in the Journal of Diabetes evaluated topical PL-5 (peceleganan) spray alongside standard debridement in patients with mildly to moderately infected diabetic foot ulcers. The study reported a significantly higher clinical response rate than placebo and improved clearance of drug-resistant bacteria (71.43% vs. 50%). Further research is needed to establish its broader clinical role and regulatory status.

• In May 2026, Flen Health Pharma NV, a Belgium-based biopharmaceutical company specializing in wound and skin healing therapies for over 25 years, announced that it has received favorable written feedback from the U.S. FDA following an INTERACT (Initial Targeted Engagement for Regulatory Advice on CBER/CDER Products) meeting for its investigational biologic, VES gel. The FDA provided recommendations regarding the product’s Chemistry, Manufacturing and Controls (CMC) and nonclinical development strategy, representing an important regulatory advancement. This feedback supports the company’s ongoing efforts to progress VES gel, a novel therapy aimed at accelerating the healing of chronic diabetic foot ulcers (DFUs), toward an Investigational New Drug (IND) application submission.

• In November 2025, Kane Biotech Inc. (TSX-V: KNE) announced new clinical and preclinical results showcasing the effectiveness of its FDA-cleared revyve® Antimicrobial Wound Gel and revyve Wound Gel Spray in promoting healing in diabetic foot ulcers and managing burn wound infections. The data were recently presented at two major U.S. medical conferences, including the Diabetic Foot Conference.

• In October 2025, Celularity Inc. reported positive results from its Phase 2 clinical trial of PDA-002, a first-in-class regenerative therapy designed for treating diabetic foot ulcers (DFUs) complicated by peripheral artery disease (PAD). Published in the International Wound Journal, the study revealed that two doses of PDA-002, derived from placenta cells, led to significant wound healing, particularly in patients with PAD. This therapy is especially noteworthy as there are currently no FDA-approved treatments targeting DFUs associated with PAD, a condition impacting around two million people in the U.S. each year. The findings demonstrated enhanced healing rates, fewer complications, and a strong safety profile, underscoring PDA-002’s potential to meet a major unmet need in wound care.

• In July 2025, Eluciderm Inc. has obtained FDA clearance for its Investigational New Drug (IND) application to initiate a Phase I/IIa open-label trial. The study will assess the safety and effectiveness of ELU-42, a topical spray-on solution designed to promote healing in patients with diabetic foot ulcers (DFUs).

• In January 2025, BioStem Technologies, Inc. (OTC: BSEM), a prominent MedTech firm specializing in placental-based products for advanced wound healing, has launched the BR-AM-DFU (BioREtain® Amniotic Membrane – Diabetic Foot Ulcers) clinical trial. This study will assess the effectiveness of Vendaje® compared to the current standard of care in treating non-healing diabetic foot ulcers.

Diabetic Foot Ulcers Overview

Diabetic Foot Ulcers (DFUs) are open sores or wounds that develop on the feet of people with diabetes, often due to peripheral neuropathy, poor blood circulation, and impaired wound healing. These ulcers commonly occur on the soles of the feet and can lead to serious complications, including infections, tissue damage, and lower-limb amputations if left untreated. Major risk factors include prolonged diabetes, high blood glucose levels, foot deformities, and peripheral arterial disease. Treatment options include wound care, pressure offloading, infection management, and advanced therapies such as skin substitutes and growth factor-based treatments. Early diagnosis and proper foot care are essential to prevent complications and improve patient outcomes.

Explore the latest Diabetic Foot Ulcers pipeline insights 2026, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Diabetic Foot Ulcers Clinical Trials

Emerging Diabetic Foot Ulcers Drugs Under Different Phases of Clinical Development Include:

• TOP-N53: Topadur Pharma

• CYP-006TK: Cynata Therapeutics

• TWB-103: Transwell Biotech

• APO-2: Aposcience

• ILP100: Ilya Pharma

• MBN-101: Microbion Corporation

• EscharEx: MediWound

• Adipose-derived regenerative cells: Paracrine, INC.

• Galnobax: NovaLead Pharma

Diabetic Foot Ulcers Route of Administration

Diabetic Foot Ulcers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Diabetic Foot Ulcers Molecule Type

Diabetic Foot Ulcers Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Diabetic Foot Ulcers Pipeline Therapeutics Assessment

• Diabetic Foot Ulcers Assessment by Product Type

• Diabetic Foot Ulcers By Stage and Product Type

• Diabetic Foot Ulcers Assessment by Route of Administration

• Diabetic Foot Ulcers By Stage and Route of Administration

• Diabetic Foot Ulcers Assessment by Molecule Type

• Diabetic Foot Ulcers by Stage and Molecule Type

DelveInsight’s Diabetic Foot Ulcers Report covers around 25+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Diabetic Foot Ulcers product details are provided in the report. Download the Diabetic Foot Ulcers pipeline report to learn more about the emerging Diabetic Foot Ulcers therapies

Some of the key companies in the Diabetic Foot Ulcers Therapeutics Market include:

Key companies developing therapies for Diabetic Foot Ulcers are – Medline, B. Braun, Organogenesis, 3M, Smith & Nephew, Molnlycke Health Care, ConvaTec, Coloplast, Integra LifeSciences, Essity (BSN Medical), and others.

Diabetic Foot Ulcers Pipeline Analysis:

The Diabetic Foot Ulcers pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Foot Ulcers with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Foot Ulcers Treatment.

• Diabetic Foot Ulcers key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Diabetic Foot Ulcers Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Foot Ulcers market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Diabetic Foot Ulcers drugs and therapies

Diabetic Foot Ulcers Pipeline Market Drivers

• Rise in global prevalence of foot ulcers in diabetic patients, increasing research and development activities in the development of biologics, technological advancements are some of the important factors that are fueling the Diabetic Foot Ulcers Market.

Diabetic Foot Ulcers Pipeline Market Barriers

• However, high cost of the advanced wound care therapies, adverse effects associated with the drugs and other factors are creating obstacles in the Diabetic Foot Ulcers Market growth.

Scope of Diabetic Foot Ulcers Pipeline Drug Insight

• Coverage: Global

• Key Diabetic Foot Ulcers Companies: Topadur Pharma, Cynata Therapeutics, Transwell Biotech, Aposcience, Ilya Pharma, Microbion Corporation, MediWound, Paracrine, INC., NovaLead Pharma, and others

• Key Diabetic Foot Ulcers Therapies: TOP-N53, CYP-006TK, TWB-103, APO-2, ILP100, MBN-101, EscharEx, Adipose-derived regenerative cells, Galnobax, and others

• Diabetic Foot Ulcers Therapeutic Assessment: Diabetic Foot Ulcers current marketed and Diabetic Foot Ulcers emerging therapies

• Diabetic Foot Ulcers Market Dynamics: Diabetic Foot Ulcers market drivers and Diabetic Foot Ulcers market barriers

Request for Sample PDF Report for Diabetic Foot Ulcers Pipeline Assessment and clinical trials

Table of Contents

1. Diabetic Foot Ulcers Report Introduction

2. Diabetic Foot Ulcers Executive Summary

3. Diabetic Foot Ulcers Overview

4. Diabetic Foot Ulcers- Analytical Perspective In-depth Commercial Assessment

5. Diabetic Foot Ulcers Pipeline Therapeutics

6. Diabetic Foot Ulcers Late Stage Products (Phase II/III)

7. Diabetic Foot Ulcers Mid Stage Products (Phase II)

8. Diabetic Foot Ulcers Early Stage Products (Phase I)

9. Diabetic Foot Ulcers Preclinical Stage Products

10. Diabetic Foot Ulcers Therapeutics Assessment

11. Diabetic Foot Ulcers Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Diabetic Foot Ulcers Key Companies

14. Diabetic Foot Ulcers Key Products

15. Diabetic Foot Ulcers Unmet Needs

16 . Diabetic Foot Ulcers Market Drivers and Barriers

17. Diabetic Foot Ulcers Future Perspectives and Conclusion

18. Diabetic Foot Ulcers Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/